Literature DB >> 16136637

The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke.

Daniel M Cook1, Elisa K Tong, Stanton A Glantz, Lisa A Bero.   

Abstract

A new medical diagnostic code for secondhand smoke exposure became available in 1994, but as of 2004 it remained an invalid entry on a common medical form. Soon after the code appeared, Philip Morris hired a Washington consultant to influence the governmental process for creating and using medical codes. Tobacco industry documents reveal that Philip Morris budgeted more than $2 million for this "ICD-9 Project." Tactics to prevent adoption of the new code included third-party lobbying, Paperwork Reduction Act challenges, and backing an alternative coding arrangement. Philip Morris's reaction reveals the importance of policy decisions related to data collection and paperwork.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136637     DOI: 10.1377/hlthaff.24.4.994

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  When tobacco targets direct democracy.

Authors:  Elizabeth Laposata; Allison P Kennedy; Stanton A Glantz
Journal:  J Health Polit Policy Law       Date:  2014-03-06       Impact factor: 2.265

2.  Tobacco Industry Influence on the American Law Institute's Restatements of Torts and Implications for Its Conflict of Interest Policies.

Authors:  Elizabeth Laposata; Richard Barnes; Stanton Glantz
Journal:  Iowa Law Rev       Date:  2012-11

3.  Participation and argument in legislative debate on statewide smoking restrictions.

Authors:  Dorie E Apollonio; Peggy Lopipero; Lisa A Bero
Journal:  Health Res Policy Syst       Date:  2007-10-22

4.  Tobacco company efforts to influence the Food and Drug Administration-commissioned Institute of Medicine report clearing the smoke: an analysis of documents released through litigation.

Authors:  Crystal E Tan; Thomas Kyriss; Stanton A Glantz
Journal:  PLoS Med       Date:  2013-05-28       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.